Last reviewed · How we verify
Lamotrigine regular tablet formulation
Lamotrigine blocks voltage-gated sodium channels and inhibits glutamate release, reducing neuronal excitability.
Lamotrigine blocks voltage-gated sodium channels and inhibits glutamate release, reducing neuronal excitability. Used for Epilepsy (adjunctive therapy for partial seizures), Bipolar I disorder (maintenance treatment to delay time to occurrence of mood episodes).
At a glance
| Generic name | Lamotrigine regular tablet formulation |
|---|---|
| Also known as | Lamictal |
| Sponsor | University Hospitals Cleveland Medical Center |
| Drug class | Anticonvulsant / Mood stabilizer |
| Target | Voltage-gated sodium channels; glutamate release inhibition |
| Modality | Small molecule |
| Therapeutic area | Neurology / Psychiatry |
| Phase | Phase 3 |
Mechanism of action
Lamotrigine stabilizes neuronal membranes by blocking sodium channels, which prevents repetitive neuronal firing. It also inhibits the release of glutamate, an excitatory neurotransmitter, thereby reducing excessive neuronal activity. These combined effects make it effective as an anticonvulsant and mood stabilizer.
Approved indications
- Epilepsy (adjunctive therapy for partial seizures)
- Bipolar I disorder (maintenance treatment to delay time to occurrence of mood episodes)
Common side effects
- Rash (including Stevens-Johnson syndrome risk)
- Dizziness
- Ataxia
- Somnolence
- Headache
- Diplopia
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: